Spinal cord injury treatment raises hope
New Scientist, 12 June 04
By Helen Phillips
The initial trial of a controversial method for treating
spinal cord injuries within two weeks of an accident suggests it
may be partly successful. More patients recovered some sensation
and movement than would normally be expected, the company behind
the trial claims.
Independent experts say the results look promising, but caution
that with just 16 people treated so far, it is too early to draw
any conclusions. Some worry that the technique is risky and
could cause serious problems in the long term.
The method involves extracting immune cells from a patient's
blood, "activating" them by incubating them with skin cells, and
then injecting the cells directly into the damaged spinal cord.
This must all be done within 14 days of the injury, so even if
larger trials confirm its benefits, the method will not help the
hundreds of thousands of people worldwide with existing
injuries.
The technique is being developed by ProNeuron Biotechnologies of
Los Angeles, California, which has just submitted results from
the first 10 patients for publication.
All patients fell into the most severe spinal injury category,
called ASIA-A. This is defined as having no sensation or ability
to move below the site of injury. Normal sensation and movement
is defined as ASIA-E.
Muscle function
According to David Snyder, vice-president of clinical
development at ProNeuron, three of the 16 patients treated so
far (19 per cent) have recovered some weak muscle function,
which means they are now classed ASIA-C. One has regained
bladder control, while another can stand and walk with
assistance. This degree of recovery can occur spontaneously, but
Snyder says less than four per cent of patients normally recover
from ASIA-A to C.
Two other patients (13 per cent) have regained some sensation,
and are now classed as ASIA-B. About 10 per cent of patients
normally recover to ASIA-B. Four other patients show signs that
nerve signals can pass through the injury site, though as yet
they have no significant functional recovery.
Snyder describes the results as a good start. Most importantly
for a phase I trial, which is designed to assess safety rather
than effectiveness, he says there were no signs of any ill
effects. On the basis of the results, ProNeuron announced this
week that phase II trials will go ahead in the US. It aims to
recruit 61 patients within the year.
"The early data is encouraging," says Phillip Popovich of Ohio
State University in Columbus. But since there was no control
group, the improvements could just be a result of the emotional
boost the treatment gives patients, he points out.
Clean up
The therapy is based on the work of Michal Schwartz of the
Weizmann Institute of Science in Rehovot, Israel. Her theory is
that one of the reasons for the poor healing of spinal injuries
is that the central nervous system is partly isolated from the
immune system.
It takes months for immune cells called macrophages, which clean
up damaged tissue and promote healing by releasing growth
factors, to accumulate at a spinal injury site. Her animal
studies suggested injecting the cells soon after the injury can
help recovery (New Scientist print edition, 4 July 1998).
But many researchers remain unconvinced. "Whether macrophages
are damaging or beneficial is very controversial," says Geoff
Raisman, who works on spinal cord injury at the National
Institute for Medical Research in London, UK.
There is even a risk that the treatment could make things worse,
warns Mark Tuszynski at the University of California, San Diego.
"This could hypothetically cause a loss of function in
critically valuable tissue that is spared just above the
lesion," he says. Tuszynski would prefer to see the animal
results replicated in an independent lab before being tried in
humans.
Although no patients have shown any signs of damage, it could
occur much later, Popovich warns. Animal studies show that
macrophages can remain at the injury site for years. An
inflammatory reaction sparked by infection or surgery might
damage any nerves that have recovered, he says.
© Copyright Reed Business Information Ltd.